Did you know?

Highlighted announcements: Expects total fourth quarter revenue of $645.5-$647.5 million, an increase of 17% compared to the fourth quarter of 2022, with Screening revenue of $486.0-$487.0 million and Precision Oncology revenue of $159.5 - $160.5 million. Expects total full-year 2023 revenue of $2.50 billion and 2024 revenue of $2.83 …Exact Sciences Corporation (NASDAQ:EXAS) Q2 2023 Earnings Call Transcript August 1, 2023 5:00 PM ET. Company Participants. Megan Jones - Vice President of Investor Relations View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ. View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ. Discover real-time Exact Sciences Corporation Common Stock (EXAS) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq. Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $628.3 million for the third quarter ended September 30, 2023, compared to $523.1 million for the same period of 2022. "Exact Sciences' third-quarter results reflect our unwavering dedication to improving cancer care on a global scale," said ...Exact Sciences Corporation is a molecular diagnostics company that focuses on the early detection and prevention of colorectal cancer. The company launched Cologuard in 2014, the first stool DNA test for colorectal cancer. In July 2019, Exact Sciences acquired Genomic Health, a genetic cancer detection company, for $2.8B. Cologuard uses a biomarker panel which analyzes a person’s stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin). This multi-marker approach is a distinguishing feature of Exact Sciences’ scientific platform. Cologuard finds colon cancer even in early stages when it is more treatable. 1,2,3* Cologuard is convenient. Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and ...Team building activities have become a popular trend in the corporate world, as organizations recognize the importance of fostering a positive and cohesive work environment. Effect...View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ.Data Presented Include Prospective and Case-collected Samples and Show Improved Specificity of 92%, High Sensitivity for Colorectal Cancer at 95%, and Precancerous Lesion Sensitivity of 57% Data Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) Exact Sciences and Mayo …Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $456.4 million for the third quarter ended September 30, 2021, compared to $408.4 million for the same period of 2020. "Exact Sciences is entering an exciting period for its pipeline, generating evidence to support innovative tests that will help defeat …The production of green hydrogen, which is most effectively generated when catalysed by platinum group metals (PGMs), has profound economic and social …Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced new data supporting its cancer tests and treatment guidance tools will be showcased in nine poster presentations and five e-abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 3-7 in …Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $466.3 million for the fourth quarter ended Dec. 31, 2020 and $1,491.4 million for the full year ended Dec. 31, 2020. "Exact Sciences finished another transformative year by delivering strong fourth quarter results against a challenging …Mar 28, 2024 · MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, in collaboration with Mayo Clinic Comprehensive Cancer Center, reported on data showing high sensitivity and specificity for the non-endoscopic Oncoguard ® Esophagus test that is currently in development for the detection of esophageal adenocarcinoma (EAC) and its ... MADISON, Wis., June 20, 2023 – Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced positive top-line results from the pivotal BLUE-C study. The results show that next-generation Cologuard ® met all study endpoints and improved every top-line metric, including a 30 percent lower false …Jan 7, 2024 · MADISON, Wis., Jan. 7, 2024 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report ... A high-level overview of Exact Sciences Corporation (EXAS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. MADISON, Wis., May 08, 2024--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $638 million ...Are you a homeschooling parent looking for a free science curriculum to enhance your child’s education? Look no further. In this article, we will explore some of the best free home...Jan 9, 2022 · Stephanie Spanos, [email protected], 608-556-4380. Exact Sciences Investor Contact: Megan Jones, [email protected], 608-535-8815. OncXerna Investor and Media Contact: Ashley R. Robinson, LifeSci Partners, LLC, [email protected]. [1]Chau, I. Phase 2 Study of Bavituximab, a First-in-class Antibody Targeting ... Exact Sciences Corporation (NASDAQ:EXAS) Q4 2023 Earnings Call Transcript February 21, 2024 5:00 PM ET. Company Participants. Nate Harrill - VP of IR Kevin Conroy - Chairman and CEO Jeff Elliott - CFOEarnings estimates for Haemonetics have increased from $3.86 to $7 days ago ... Exact Sciences and Cologuard are Data from Prospective, Observational Study will Strengthen Clinical Evidence and Support Continued Cologuard Adoption (NASDAQ: EXAS) – Exact Sciences Corp. today announced that, in collaboration with Mayo Clinic, it has initiated the Voyage study to generate evidence of the real-world impact of Cologuard on colorectal cancer screening, …Exact Sciences is headquartered in Madison, Wisconsin, the US. Gain a 360-degree view of Exact Sciences Corp and make more informed decisions for your business Find out more. Headquarters United States of America. Address 5505 Endeavor Lane, Madison, Wisconsin, 53719. Website www.exactsciences.com. Telephone 1 608 2845700. No of … Exact Sciences’ products, services, mission, and peo Jan 9, 2022 · Exact Sciences undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise. Exact Sciences Media Contact: Katie Boyce, [email protected], 608-710-3903. Exact Sciences Investor Contact: Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $456.4 million for the third quarter ended September 30, 2021, compared to $408.4 million for the same period of 2020. "Exact Sciences is entering an exciting period for its pipeline, generating evidence to support innovative tests that will help defeat cancer through earlier detection," said Kevin Conroy ... Enter your zip code below to locate a UPS Store near you. Need

MADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $486.6 million for the first quarter ended March 31, 2022, compared to $402.1 million for the same period of 2021. Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $521.6 million for the second quarter ended June 30, 2022, compared to $434.8 million for the same period of 2021. "Exact Sciences' strong second quarter results reflect meaningful progress toward our vision to help eradicate cancer by ...Exact Sciences is a biotechnology company that develops and commercializes non-invasive cancer screening tests. Read the latest news and updates …Exact Sciences Corp. is a molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on …Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $622.1 million for the second quarter ended June 30, 2023, compared to $521.6 million for the same period of 2022. "The team at Exact Sciences is powering the most innovative …

Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $456.4 million for the third quarter ended September 30, 2021, compared to $408.4 million for the same period of 2020. "Exact Sciences is entering an exciting period for its pipeline, generating evidence to support innovative tests that will help defeat cancer through earlier detection," said Kevin Conroy ...Sep 10, 2022 · MADISON, Wis., September 10, 2022 -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced data from a multi-cancer early detection (MCED) biomarker validation study was presented at the European Society for Medical Oncology (ESMO) Congress. The study rigorously assessed the ... …

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. July 10, 2023 2:20 PM. Exact Sciences Corporation, a pr. Possible cause: Learn about the virtual-only Annual Meeting of Shareholders of Exact Sci.